KR20180067603A - Acc 억제제 및 그의 용도 - Google Patents
Acc 억제제 및 그의 용도 Download PDFInfo
- Publication number
- KR20180067603A KR20180067603A KR1020187013132A KR20187013132A KR20180067603A KR 20180067603 A KR20180067603 A KR 20180067603A KR 1020187013132 A KR1020187013132 A KR 1020187013132A KR 20187013132 A KR20187013132 A KR 20187013132A KR 20180067603 A KR20180067603 A KR 20180067603A
- Authority
- KR
- South Korea
- Prior art keywords
- grams
- independently selected
- nitrogen
- sulfur
- heteroatoms independently
- Prior art date
Links
- 0 C*([n]1nccn1)=C Chemical compound C*([n]1nccn1)=C 0.000 description 21
- ZZSJUEWJLXGBQE-CDSUDZIVSA-N C/C=C/CCOC(CN(c([s]c(-[n]1nccn1)c1C)c1C(N1[C@@H](CCN2C)C2=O)=O)C1=O)c1cc(F)ccc1OC Chemical compound C/C=C/CCOC(CN(c([s]c(-[n]1nccn1)c1C)c1C(N1[C@@H](CCN2C)C2=O)=O)C1=O)c1cc(F)ccc1OC ZZSJUEWJLXGBQE-CDSUDZIVSA-N 0.000 description 1
- UOMFGVFGLMRDEV-UHFFFAOYSA-N CC(C)N(CCC1N(C(c2c(N3)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O Chemical compound CC(C)N(CCC1N(C(c2c(N3)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O UOMFGVFGLMRDEV-UHFFFAOYSA-N 0.000 description 1
- NWYOHBLLZDTKHT-GITCGBDTSA-N CC(C)N(CCC1N(C(c2c(N3C[C@@H](c(cc(cc4)F)c4OC)OC4CCOCC4)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O Chemical compound CC(C)N(CCC1N(C(c2c(N3C[C@@H](c(cc(cc4)F)c4OC)OC4CCOCC4)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O NWYOHBLLZDTKHT-GITCGBDTSA-N 0.000 description 1
- GVJKRJYEULLCOZ-IAXKEJLGSA-N CC(C)N(CCC1N(C(c2c(N3C[C@@H](c4cc(F)ccc4OC)OCCOC)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O Chemical compound CC(C)N(CCC1N(C(c2c(N3C[C@@H](c4cc(F)ccc4OC)OCCOC)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O GVJKRJYEULLCOZ-IAXKEJLGSA-N 0.000 description 1
- GVJKRJYEULLCOZ-IRLDBZIGSA-N CC(C)N(CC[C@H]1N(C(c2c(N3C[C@@H](c(cc(cc4)F)c4OC)OCCOC)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O Chemical compound CC(C)N(CC[C@H]1N(C(c2c(N3C[C@@H](c(cc(cc4)F)c4OC)OCCOC)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O GVJKRJYEULLCOZ-IRLDBZIGSA-N 0.000 description 1
- KIKTYQZUPCXXJL-SVQMELKDSA-N CC(CCN1C)(C1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O Chemical compound CC(CCN1C)(C1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O KIKTYQZUPCXXJL-SVQMELKDSA-N 0.000 description 1
- HADXUTFMHBNPAD-IJHRGXPZSA-N CCN(CCC1N(C(c2c(N3C[C@@H](c4cc(F)ccc4OC)OCCO)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O Chemical compound CCN(CCC1N(C(c2c(N3C[C@@H](c4cc(F)ccc4OC)OCCO)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O HADXUTFMHBNPAD-IJHRGXPZSA-N 0.000 description 1
- FUIXSSLUFDMWPL-UHFFFAOYSA-N CCOC(c1c(N)[s]c(-[n]2nccc2)c1C)=O Chemical compound CCOC(c1c(N)[s]c(-[n]2nccc2)c1C)=O FUIXSSLUFDMWPL-UHFFFAOYSA-N 0.000 description 1
- ZXQUAKUBBSEBCD-UHFFFAOYSA-N CCOC(c1c(NC(NC(CCCN2C)C2=O)=O)[s]c(-[n]2nccc2)c1C)=O Chemical compound CCOC(c1c(NC(NC(CCCN2C)C2=O)=O)[s]c(-[n]2nccc2)c1C)=O ZXQUAKUBBSEBCD-UHFFFAOYSA-N 0.000 description 1
- FSYXJZFACRSSHN-UHFFFAOYSA-N COCC/[O]=C(/CO)\c1cc(F)ccc1OC Chemical compound COCC/[O]=C(/CO)\c1cc(F)ccc1OC FSYXJZFACRSSHN-UHFFFAOYSA-N 0.000 description 1
- GNRCSWVAFGZUEK-LBPRGKRZSA-N COCCO[C@@H](CO)c1cc(F)ccc1OC Chemical compound COCCO[C@@H](CO)c1cc(F)ccc1OC GNRCSWVAFGZUEK-LBPRGKRZSA-N 0.000 description 1
- BHVKAQAGKAZQDP-UHFFFAOYSA-N COc(c(C(CBr)=O)c1)ccc1F Chemical compound COc(c(C(CBr)=O)c1)ccc1F BHVKAQAGKAZQDP-UHFFFAOYSA-N 0.000 description 1
- OOAXFRZNKMCFFE-UHFFFAOYSA-N COc(c(C(CO)OCCC=C)c1)ccc1F Chemical compound COc(c(C(CO)OCCC=C)c1)ccc1F OOAXFRZNKMCFFE-UHFFFAOYSA-N 0.000 description 1
- JREKZADIKXLMTG-AWEZNQCLSA-N COc(c([C@H](CO)OC1CCOCC1)c1)ccc1F Chemical compound COc(c([C@H](CO)OC1CCOCC1)c1)ccc1F JREKZADIKXLMTG-AWEZNQCLSA-N 0.000 description 1
- BRYPDTXWGDTQFO-AFMDSPMNSA-N C[C@@](CCN1)(C1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O Chemical compound C[C@@](CCN1)(C1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O BRYPDTXWGDTQFO-AFMDSPMNSA-N 0.000 description 1
- WZSBUEKTUOJESY-UHFFFAOYSA-N Cc1c(-[n]2nccc2)[s]c(N(CCc2cc(F)ccc2OC)C(N2C(CCCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccc2)[s]c(N(CCc2cc(F)ccc2OC)C(N2C(CCCN3)C3=O)=O)c1C2=O WZSBUEKTUOJESY-UHFFFAOYSA-N 0.000 description 1
- WZSBUEKTUOJESY-KRWDZBQOSA-N Cc1c(-[n]2nccc2)[s]c(N(CCc2cc(F)ccc2OC)C(N2[C@@H](CCCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccc2)[s]c(N(CCc2cc(F)ccc2OC)C(N2[C@@H](CCCN3)C3=O)=O)c1C2=O WZSBUEKTUOJESY-KRWDZBQOSA-N 0.000 description 1
- GCPLTXHYGKXOCK-IAXKEJLGSA-N Cc1c(-[n]2nccc2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2C(CCCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccc2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2C(CCCN3C)C3=O)=O)c1C2=O GCPLTXHYGKXOCK-IAXKEJLGSA-N 0.000 description 1
- GCPLTXHYGKXOCK-IRLDBZIGSA-N Cc1c(-[n]2nccc2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2[C@H](CCCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccc2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2[C@H](CCCN3C)C3=O)=O)c1C2=O GCPLTXHYGKXOCK-IRLDBZIGSA-N 0.000 description 1
- IJRYRLPORWOLOQ-UHFFFAOYSA-N Cc1c(-[n]2nccc2)[s]c(NC(N2C(CCCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccc2)[s]c(NC(N2C(CCCN3)C3=O)=O)c1C2=O IJRYRLPORWOLOQ-UHFFFAOYSA-N 0.000 description 1
- KBXCTPDWFJDQSH-CVMIBEPCSA-N Cc1c(-[n]2nccn2)[s]c(N(CC(/C=[O]/CCC(O)=O)c2cc(F)ccc2OC)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(CC(/C=[O]/CCC(O)=O)c2cc(F)ccc2OC)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O KBXCTPDWFJDQSH-CVMIBEPCSA-N 0.000 description 1
- NBODGRXTWJWLMT-CQSZACIVSA-N Cc1c(-[n]2nccn2)[s]c(N(CC(c2cc(F)ccc2OC)=O)C(N2[C@H](CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(CC(c2cc(F)ccc2OC)=O)C(N2[C@H](CCN3)C3=O)=O)c1C2=O NBODGRXTWJWLMT-CQSZACIVSA-N 0.000 description 1
- RLAYVLXTRPAUDR-OAHLLOKOSA-N Cc1c(-[n]2nccn2)[s]c(N(CC(c2cc(F)ccc2OC)=O)C(N2[C@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(CC(c2cc(F)ccc2OC)=O)C(N2[C@H](CCN3C)C3=O)=O)c1C2=O RLAYVLXTRPAUDR-OAHLLOKOSA-N 0.000 description 1
- PXYHUIDTFMXEFX-HNNXBMFYSA-N Cc1c(-[n]2nccn2)[s]c(N(CCc2cc(F)ccc2OC)C(N2[C@@H](CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(CCc2cc(F)ccc2OC)C(N2[C@@H](CCN3)C3=O)=O)c1C2=O PXYHUIDTFMXEFX-HNNXBMFYSA-N 0.000 description 1
- QGEUWDGMAIICFC-ICSRJNTNSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OCCOC)C(N2[C@@H](CCCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OCCOC)C(N2[C@@H](CCCN3)C3=O)=O)c1C2=O QGEUWDGMAIICFC-ICSRJNTNSA-N 0.000 description 1
- ZAHLWJLQISGEOI-APWZRJJASA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OCCOC)C(N2[C@H](C3)CNC3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OCCOC)C(N2[C@H](C3)CNC3=O)=O)c1C2=O ZAHLWJLQISGEOI-APWZRJJASA-N 0.000 description 1
- WZIJKOPWNUFBIH-NNBQYGFHSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCC(O)=O)C(N2C(CCCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCC(O)=O)C(N2C(CCCN3)C3=O)=O)c1C2=O WZIJKOPWNUFBIH-NNBQYGFHSA-N 0.000 description 1
- WZIJKOPWNUFBIH-MJGOQNOKSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCC(O)=O)C(N2[C@H](CCCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCC(O)=O)C(N2[C@H](CCCN3)C3=O)=O)c1C2=O WZIJKOPWNUFBIH-MJGOQNOKSA-N 0.000 description 1
- DECKFPXFYNGOJP-CVMIBEPCSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2C(C3)CN(C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2C(C3)CN(C)C3=O)=O)c1C2=O DECKFPXFYNGOJP-CVMIBEPCSA-N 0.000 description 1
- DECKFPXFYNGOJP-LPHOPBHVSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2[C@@H](C3)CN(C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2[C@@H](C3)CN(C)C3=O)=O)c1C2=O DECKFPXFYNGOJP-LPHOPBHVSA-N 0.000 description 1
- JIGWJMZRYPTTMJ-XLIONFOSSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2[C@H](C3)CN(C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2[C@H](C3)CN(C)C3=O)=O)c1C2=O JIGWJMZRYPTTMJ-XLIONFOSSA-N 0.000 description 1
- BPUYDWZNHIWXJW-UHFFFAOYSA-N Cc1c(-[n]2nccn2)[s]c(NC(N2C(CCCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(NC(N2C(CCCN3)C3=O)=O)c1C2=O BPUYDWZNHIWXJW-UHFFFAOYSA-N 0.000 description 1
- CWYDJCNBLIRUDA-ZETCQYMHSA-N Cc1c(-[n]2nccn2)[s]c(NC(N2[C@@H](CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(NC(N2[C@@H](CCN3)C3=O)=O)c1C2=O CWYDJCNBLIRUDA-ZETCQYMHSA-N 0.000 description 1
- CWYDJCNBLIRUDA-SSDOTTSWSA-N Cc1c(-[n]2nccn2)[s]c(NC(N2[C@H](CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(NC(N2[C@H](CCN3)C3=O)=O)c1C2=O CWYDJCNBLIRUDA-SSDOTTSWSA-N 0.000 description 1
- YXYPJSHUAXGGGE-QUCCMNQESA-N Cc1c(-c2ncc[o]2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2[C@H](CCCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-c2ncc[o]2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2[C@H](CCCN3C)C3=O)=O)c1C2=O YXYPJSHUAXGGGE-QUCCMNQESA-N 0.000 description 1
- YCCMTCQQDULIFE-UHFFFAOYSA-N NC(CCCN1)C1=O Chemical compound NC(CCCN1)C1=O YCCMTCQQDULIFE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246318P | 2015-10-26 | 2015-10-26 | |
| US62/246,318 | 2015-10-26 | ||
| PCT/US2016/058867 WO2017075056A1 (en) | 2015-10-26 | 2016-10-26 | Acc inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180067603A true KR20180067603A (ko) | 2018-06-20 |
Family
ID=57233943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187013132A KR20180067603A (ko) | 2015-10-26 | 2016-10-26 | Acc 억제제 및 그의 용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10179793B2 (pt) |
| EP (1) | EP3368540A1 (pt) |
| JP (1) | JP2018538246A (pt) |
| KR (1) | KR20180067603A (pt) |
| CN (1) | CN108368125A (pt) |
| AR (1) | AR106472A1 (pt) |
| AU (1) | AU2016344392A1 (pt) |
| BR (1) | BR112018008227A2 (pt) |
| CA (1) | CA3003275A1 (pt) |
| EA (1) | EA201890749A1 (pt) |
| IL (1) | IL258636A (pt) |
| MX (1) | MX2018005292A (pt) |
| SG (1) | SG11201802989QA (pt) |
| WO (1) | WO2017075056A1 (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA123760C2 (uk) | 2011-11-11 | 2021-06-02 | Гіліад Аполло, Ллс | Сполука (варіанти) та композиція, що містить сполуку |
| CN107207444B (zh) | 2014-11-26 | 2020-07-24 | 武田药品工业株式会社 | 二环化合物 |
| BR112018010113B1 (pt) | 2015-11-25 | 2022-06-14 | Gilead Apollo, Llc | Composto de pirazol útil como inibidor da acetil-coa carboxilase (acc) |
| BR112018010453B1 (pt) | 2015-11-25 | 2022-06-14 | Gilead Apollo, Llc | Compostos triazólicos inibindores de acetil coa carboxilase (acc) |
| CN108290902B (zh) | 2015-11-25 | 2021-08-31 | 吉利德阿波罗公司 | 酯类acc抑制剂及其用途 |
| KR20180086191A (ko) | 2015-11-25 | 2018-07-30 | 길리어드 아폴로, 엘엘씨 | 2,4-디옥소-1,4-디히드로티에노[2,3-d]피리미딘 유도체를 함유하는 살진균 조성물 |
| EP3423456B1 (en) | 2016-03-02 | 2023-12-27 | Gilead Apollo, LLC | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| JP2019529452A (ja) | 2016-09-23 | 2019-10-17 | バイエル・アクチエンゲゼルシヤフト | Ｎ３−環状置換チエノウラシルおよびその使用 |
| CN108341830B (zh) | 2017-01-22 | 2021-03-02 | 广东东阳光药业有限公司 | 噻吩并嘧啶衍生物及其在药物中的应用 |
| KR20190125359A (ko) * | 2017-03-03 | 2019-11-06 | 길리어드 아폴로, 엘엘씨 | 살진균 화합물의 제조 방법 |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| WO2018228369A1 (zh) * | 2017-06-15 | 2018-12-20 | 浙江海正药业股份有限公司 | 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 |
| CN110959007B (zh) * | 2017-07-26 | 2022-07-01 | 南京圣和药业股份有限公司 | 作为acc抑制剂的化合物及其应用 |
| CA3094988A1 (en) | 2018-03-30 | 2019-10-03 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| EP3805230B1 (en) | 2018-06-05 | 2024-08-07 | Medshine Discovery Inc. | Thieno[2,3-c]pyridazin-4(1h)-one derivative and application thereof |
| CA3118422A1 (en) * | 2018-11-02 | 2020-05-07 | Dow Agrosciences Llc | Compositions comprising halauxifen and other herbicides and methods thereof |
| US20220041616A1 (en) * | 2018-11-20 | 2022-02-10 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Spiro compound and medical uses thereof |
| CN111484504B (zh) * | 2019-01-25 | 2024-05-10 | 南京圣和药业股份有限公司 | Acc抑制剂的光学异构体及其应用 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| CN110746439B (zh) * | 2019-10-18 | 2020-10-30 | 南京瑞捷医药科技有限公司 | 一种噻吩并嘧啶二酮化合物的制备方法 |
| WO2021112213A1 (ja) * | 2019-12-05 | 2021-06-10 | 日本曹達株式会社 | ２，４－ジオキソ－１，４－ジヒドロチエノピリミジン化合物、及びそれを含有する農園芸用殺菌剤又は医療用・動物用抗真菌剤 |
| US11578081B1 (en) | 2019-12-05 | 2023-02-14 | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof |
| EP4071153B1 (en) | 2019-12-05 | 2023-08-23 | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Crystal form of thieno[2,3-c]pyridazine-4(1h)-one compound, preparation method therefor and use thereof |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| CN113968871A (zh) * | 2020-07-25 | 2022-01-25 | 南京圣和药业股份有限公司 | 苯基取代类acc抑制剂的晶型 |
| WO2022133097A1 (en) * | 2020-12-17 | 2022-06-23 | Biogen Ma Inc. | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels |
| US20240083908A1 (en) | 2020-12-24 | 2024-03-14 | Modulus Discovery, Inc. | Tetrahydrothienopyrimidinesulfonamide compounds |
| WO2022268520A1 (de) * | 2021-06-21 | 2022-12-29 | Bayer Aktiengesellschaft | Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen. |
| CN115677551A (zh) * | 2021-12-28 | 2023-02-03 | 武汉市振邦生物科技有限公司 | 一种2-氧代吡咯烷-3-甲酸乙酯的制备工艺 |
| WO2024031089A1 (en) | 2022-08-05 | 2024-02-08 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
| CN115433756B (zh) * | 2022-08-30 | 2024-04-09 | 山东新华制药股份有限公司 | 一种泼尼松龙的制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670560A (en) * | 1986-04-28 | 1987-06-02 | Ortho Pharmaceutical Corporation | Thienopyrimidine-2,4-dione derivatives and intermediates thereof |
| US4835157A (en) * | 1988-03-15 | 1989-05-30 | Ortho Pharmaceutical Corporation | Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents |
| JPH02225485A (ja) | 1989-02-27 | 1990-09-07 | Taiho Yakuhin Kogyo Kk | チエノピリミジン―３―酢酸誘導体 |
| JP3035745B2 (ja) * | 1990-02-22 | 2000-04-24 | 武田薬品工業株式会社 | 縮合チオフェン誘導体 |
| JP3811196B2 (ja) | 1993-08-26 | 2006-08-16 | 武田薬品工業株式会社 | エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法 |
| TW276256B (pt) | 1993-08-26 | 1996-05-21 | Takeda Pharm Industry Co Ltd | |
| CA2227384A1 (en) | 1995-08-17 | 1997-02-27 | Toshifumi Watanabe | Thienopyrimidine derivatives, their production and use |
| JPH09110873A (ja) | 1995-08-17 | 1997-04-28 | Takeda Chem Ind Ltd | チエノピリミジン誘導体、その製造法および用途 |
| JP2007302703A (ja) | 1996-04-30 | 2007-11-22 | Takeda Chem Ind Ltd | 医薬組成物 |
| US6015789A (en) | 1996-04-30 | 2000-01-18 | Takeda Chemical Industries, Ltd. | Combined use of GnRH agonist and antagonist |
| SE9702001D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| US6984644B2 (en) | 1997-05-28 | 2006-01-10 | Astrazeneca Ab | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones |
| DE19754082A1 (de) | 1997-12-05 | 1999-06-10 | Knoll Ag | Methode zur Bekämpfung der Fettleibigkeit |
| US6166019A (en) * | 1998-07-16 | 2000-12-26 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
| EP1171442B1 (en) | 1999-04-09 | 2005-12-07 | Cell Therapeutics, Inc. | Xanthine derivatives and analogs as cell signalling inhibitors |
| WO2002064598A1 (en) * | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| JP5072166B2 (ja) * | 2002-01-30 | 2012-11-14 | 武田薬品工業株式会社 | チエノピリミジン化合物、その製造法および用途 |
| EA200400980A1 (ru) | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| WO2004060058A2 (en) | 2003-01-06 | 2004-07-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Herbicides inhibiting the action of plant acetyl-coa carboxylase for use as pesticides. |
| KR101074462B1 (ko) | 2003-01-29 | 2011-10-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 티에노피리미딘 화합물 및 그 용도 |
| WO2006014647A2 (en) | 2004-07-21 | 2006-02-09 | Athersys, Inc. | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
| JP2009528389A (ja) | 2006-03-02 | 2009-08-06 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ａアデノシン受容体拮抗剤 |
| US8501750B2 (en) | 2007-05-21 | 2013-08-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| ES2445537T3 (es) | 2009-12-29 | 2014-03-03 | Poxel | Activadores de tieno[2,3-b]piridinadiona de AMPK y usos terapéuticos de los mismos |
| CA2799416A1 (en) * | 2010-05-14 | 2011-11-17 | University Of Rochester | Compositions and methods for targeting a3g:rna complexes |
| UA123760C2 (uk) * | 2011-11-11 | 2021-06-02 | Гіліад Аполло, Ллс | Сполука (варіанти) та композиція, що містить сполуку |
| BR112015028214A2 (pt) | 2013-05-10 | 2017-07-25 | Nimbus Apollo Inc | inibidores de acc e usos dos mesmos |
| CN105358154A (zh) | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| AU2014262546B2 (en) | 2013-05-10 | 2018-11-08 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| JP6417401B2 (ja) | 2013-05-10 | 2018-11-07 | ギリアド アポロ， エルエルシー | Ａｃｃ阻害剤及びその使用 |
| TWI652012B (zh) | 2013-05-20 | 2019-03-01 | 杜邦股份有限公司 | 殺真菌吡唑的固態形式 |
| WO2015007451A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| WO2015007453A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| CN108290902B (zh) | 2015-11-25 | 2021-08-31 | 吉利德阿波罗公司 | 酯类acc抑制剂及其用途 |
| KR20180086191A (ko) | 2015-11-25 | 2018-07-30 | 길리어드 아폴로, 엘엘씨 | 2,4-디옥소-1,4-디히드로티에노[2,3-d]피리미딘 유도체를 함유하는 살진균 조성물 |
| BR112018010113B1 (pt) | 2015-11-25 | 2022-06-14 | Gilead Apollo, Llc | Composto de pirazol útil como inibidor da acetil-coa carboxilase (acc) |
| BR112018010453B1 (pt) | 2015-11-25 | 2022-06-14 | Gilead Apollo, Llc | Compostos triazólicos inibindores de acetil coa carboxilase (acc) |
| EP3423456B1 (en) | 2016-03-02 | 2023-12-27 | Gilead Apollo, LLC | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
-
2016
- 2016-10-25 AR ARP160103255A patent/AR106472A1/es unknown
- 2016-10-26 MX MX2018005292A patent/MX2018005292A/es unknown
- 2016-10-26 CA CA3003275A patent/CA3003275A1/en not_active Abandoned
- 2016-10-26 EP EP16791253.4A patent/EP3368540A1/en not_active Withdrawn
- 2016-10-26 AU AU2016344392A patent/AU2016344392A1/en not_active Abandoned
- 2016-10-26 CN CN201680072737.1A patent/CN108368125A/zh active Pending
- 2016-10-26 SG SG11201802989QA patent/SG11201802989QA/en unknown
- 2016-10-26 US US15/334,955 patent/US10179793B2/en not_active Expired - Fee Related
- 2016-10-26 WO PCT/US2016/058867 patent/WO2017075056A1/en active Application Filing
- 2016-10-26 EA EA201890749A patent/EA201890749A1/ru unknown
- 2016-10-26 BR BR112018008227A patent/BR112018008227A2/pt not_active Application Discontinuation
- 2016-10-26 KR KR1020187013132A patent/KR20180067603A/ko unknown
- 2016-10-26 JP JP2018521087A patent/JP2018538246A/ja active Pending
-
2018
- 2018-04-11 IL IL258636A patent/IL258636A/en unknown
- 2018-11-27 US US16/201,571 patent/US20190330224A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018008227A2 (pt) | 2018-10-23 |
| WO2017075056A1 (en) | 2017-05-04 |
| MX2018005292A (es) | 2018-08-01 |
| US20170145028A1 (en) | 2017-05-25 |
| US20190330224A1 (en) | 2019-10-31 |
| JP2018538246A (ja) | 2018-12-27 |
| IL258636A (en) | 2018-06-28 |
| EA201890749A1 (ru) | 2018-11-30 |
| CN108368125A (zh) | 2018-08-03 |
| AR106472A1 (es) | 2018-01-17 |
| US10179793B2 (en) | 2019-01-15 |
| SG11201802989QA (en) | 2018-05-30 |
| AU2016344392A1 (en) | 2018-05-10 |
| EP3368540A1 (en) | 2018-09-05 |
| CA3003275A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10800791B2 (en) | Triazole ACC inhibitors and uses thereof | |
| US10179793B2 (en) | ACC inhibitors and uses thereof | |
| US10472374B2 (en) | ACC inhibitors and uses thereof | |
| KR20180082556A (ko) | 피라졸 acc 억제제 및 그의 용도 | |
| KR20180082558A (ko) | 에스테르 acc 억제제 및 그의 용도 | |
| TW201400489A (zh) | Ａｃｃ抑制劑及彼等之用途 | |
| NZ738735B2 (en) | ACC inhibitors and uses thereof | |
| NZ624819B2 (en) | Acc inhibitors and uses thereof |